As I think through my participation in these clinical trials, I can't help but visualize (and share) the normal sequence of events for treatment and surveillance for 10 years, which is my specific case. I am non-BRCA positive, triple positive (HER2+/HR+), early stage (2), no lymph node involvement, no metastatic disease, and non-pathologic complete response after neoadjuvant chemotherapy and lumpectomy for removal of tumor. Add in the findings solely due to participation in the clinical trial that I have disseminated tumor cells knowing that this knowledge is not available to anyone not on a clinical trial testing for these. Change even ONE of these factors, and things can drastically change for ongoing surveillance and recurrence risk.
➕ = Decreased recurrence risk
➖ = Increased recurrence risk
Non-BRCA Positive ➕
Triple Positive ➖
Early Stage ➕
No Lymph Node Involvement ➕
No Metastatic Disease ➕
Non-Pathologic Complete Response ➖
Disseminated Tumor Cells Present ➖
I'll explain the ➖ as they have the most impact in my cancer coming back. The assumption in the recurrence rates is that the person is being treated with best known evidence based treatments and following their treatment protocol accurately. The exception to others in their known recurrence is the additional knowledge I have of present disseminated tumor cells.:
- Triple Positive Status
- Being HER2+ has a high 5 year recurrence rate of 10% to 30% with most recurrences occurring within the first 2-5 years
- Being HR+ has a high 5+ year recurrence rate as the risk does not drop to zero at 5 years. A steady, persistent annual risk of late recurrence continues for 10, 15, or 20+ years.
- Non-Pathologic Complete Response
- Recurrence risk within 3 years is 7.8% to 10.3%
- Disseminated Tumor Cells - would not have known this had I not done the clinical trial
- Roughly 3- to 4-fold higher risk of late distant recurrence compared to those who have cleared the cells from their bone marrow. For HR+ breast cancer, this risk does not peak early; instead, it remains a steady, constant threat that can stretch out 5, 10, or even 20 years post-diagnosis.
***I've been asked this and never knew, so here's the difference if my cancer would have been HER2-/HR+.
- HER2-/HR+ status, the risk of recurrence is spread out over a longer time, with a steady risk that can continue past 5 years. It carries the same steady, persistent annual risk of late recurrence with due to the positive HR+ status.
I found this visual on current accepted treatment:
This is current monitoring for specifically Triple Positive Non-BRCA Breast Cancer for 10-year survivorship without any additional knowledge of disseminated tumor cells:
No comments:
Post a Comment